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Background: Transillumination using a light wand is an alternative type of laryngoscope used for tracheal intubation. 
There is little information available on the effect-site concentration of remifentanil required to control hemodynamic 
changes induced by tracheal intubation using the transillumination method during total IV anesthesia. We therefore 
conducted this study to determine the effect-site concentration of remifentanil blunting hemodynamic responses 
after tracheal intubation in patients receiving propofol anesthesia.
Methods: We enrolled 26 healthy adult patients (ASA physical status I-II), aged 16-67 scheduled for surgery within 
2 hours. All patients received a target-controlled infusion of 4 μg/ml propofol. The effect-site target-concentration of 
remifentanil of 5.0 ng/ml was chosen for the first patient. We used the Dixon’s up-and-down sequential allocation 
method for determining the next remifentanil concentration. The time required for tracheal intubation was measured 
as the level of intubation stimulation.
Results: The average intubation time was 13.9 ± 9.1 seconds. From the Dixon’s method, the EC50 of remifentanil 
blunting the hemodynamic response to tracheal intubation was 2.94 ng/ml.
Conclusions: This study shows that effect-site concentrations of remifentanil of 2.94 ng/ml is effective in blunting 
sympathetic responses to tracheal intubation in 50% of patients with normal airway anatomy when combined with a 
target controlled infusion of propofol (4 μg/ml). (Korean J Anesthesiol 2011; 60: 398-402)
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Introduction
    Tracheal intubation commonly results in sympathetic stimu-
lation manifested by hemodynamic change such as increased 
heart rate and arterial blood pressure. The strength of stimu-
lation during laryngoscopic intubation is expressed as the 
product of its average force and duration [1]. Theoretically, 
use of the transillumination method for tracheal intubation 
may cause less adrenergic stimulation, because stimulation 
to epiglottis by laryngoscope is not required. However, many 
studies show that intubation with the transillumination method 
also increases blood pressure similar to direct laryngoscope 
[2,3]. Therefore, intubation with the transillumination method 
requires drugs for preventing hemodynamic changes due to 
sympathetic stimulation. 
    Remifentanil is a selective and strong opioid for the mu-
receptor. It has rapid onset, short duration, and context-sensitive 
time is 4 minutes. Therefore, it is widely used for endotracheal 
intubation to blunt hemodynamic response. This study is 
designed to find the effect-site concentration of remifentanil 
required for blunting hemodynamic responses after tracheal 
intubation with Surch-Lite
Ⓡ (Aron Medical, USA), accompanied 
by target-controlled infusion of 4 μg/ml of propofol.
Materials and Methods
    After obtaining approval from our institutional review board 
and informed consent from each patient, we studied 26 ASA 
physical status I or II patients, between the ages of 16 and 
65, scheduled for surgery within 2 hours. Characteristics of 
the patients and intubation time are shown in Table 1. There 
were 24 patients with Mallampati class I and 2 with class II. 
We excluded patients with Mallampati class III or IV, obese 
patients (body mass index > 30). Patients with a history of 
previous difficult intubation or in whom a difficult intubation 
was suspected were also excluded. In addition, patients with a 
known abnormal airway, limited cervical spine movement and 
patients with current use of any cardiovascular medication were 
also excluded. 
    Thirty minutes before the induction of anesthesia, patients 
were premedicated with glycopyrrolate 0.2 mg intramuscularly. 
After arrival in the operating room, non-invasive blood pressure, 
pulse oximetry and ECG were applied to patients. Ringer’s 
lactate solution (8-10 ml/kg) was infused for replacement of 
deficit of the fast during 10-20 minutes. Systolic blood pressure, 
diastolic blood pressure, mean arterial pressure and heart rate 
as hemodynamic indicators were recorded at the following 
times: 1) before induction of anesthesia 2) before infusion of 
remifentanil 3) reaching target of effect site concentration of 
remifentanil 4) 1 minute before tracheal intubation 5) during 
tracheal intubation and 6) repeated by 1 minute interval up to 4 
minutes after tracheal intubation. Upon arrival at the operating 
room, we assessed modified Mallampati classification (in the 
sitting position, tongue maximally forward on phonation) for 
each patient.
    Induction of anesthesia was initiated with 100% oxygen (5 L/
min) under a facemask. After propofol and remifentanil were 
applied to the target-controlled infusion system (Base Primea 
Orchestra
Ⓡ, Fresenius Vial, France), Marsh model and Minto 
model were chosen for propofol and remifentanil, respectively. 
Target-controlled infusion modes were both effect-site 
concentration infusions. Initially, an effect site concentration 
of 4 μg/ml propofol was selected. At 1 minute after propofol 
infusion, remifentanil infusion was started. After loss of 
eyelash reflex, rocuronium of 0.6 mg/kg was administered 
intravenously. More than 3 minutes after rocuronium was 
administered and the target effect-site concentration was 
reached, tracheal intubation was performed with Surch-Lite
Ⓡ. 
The first patient received an effect-site concentration of 5 ng/
ml remifentanil, then for decision of effect site concentration, 
Dixon’s up-and-down method was used [4]. When a patient 
showed an increase of either heart rate or mean arterial blood 
pressure (MAP) > 20% immediately before the start of the 
remifentanil infusion value, the effect-site concentration of 
remifentanil given to the next patient was increased to 0.5 ng/
ml remifentanil (failed response). In the absence of either heart 
rate or MAP increasing > 20% immediately before the start of 
the remifentanil infusion value, the effect-site concentration 
given to the next patient was decreased to 0.5 ng/ml (successful 
response). Tracheal intubation for all patients was performed 
by a faculty member who had experience with more than 100 
tracheal intubation procedures using Surch-Lite
Ⓡ. We used 
7.5-mm-ID endotracheal tubes for men and 7.0-mm-ID for 
female patients. The distal end of the light wand and covering 
lubricated tube was bent at a 90
o angle (“hockey stick”), and 
the patient’s head and neck were placed in the neutral position. 
The jaw was lifted forward by the non-dominant hand of the 
anesthesiologist and the light wand and tube were inserted. 
The ambient light was dimmed to allow the visualization of 
Table 1. Demographic Data for the Patients Enrolled in This Study
Value
Age (yr)
Sex (M/F)
Weight (Kg)
Height (cm)
Mallampati classification (I/II)
Intubation time (sec)
30.3 ± 1.1
  12/14
60.2 ± 2.8
166.7 ± 7.8
24/2
13.9 ± 9.1
Age, weight, height and intubation time are expressed as mean ± SD. 
Others are expressed as number of patients.400 www.ekja.org
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transillumination. The cuff of the tracheal tube was inflated 
immediately after withdrawal of the light wand. The intubation 
time was also recorded, which was defined as the time required 
from jaw lifting to the removal of the device in the tracheal 
tube. If the heart rate of patients was less than 50 beat/min, 
0.5 mg atropine was administered intravenously. If mean 
arterial pressure was less than 50 mmHg, 5 mg ephedrine was 
administered intravenously.
    Data was expressed as mean ± SD. Statistical analysis was 
performed with the S-PLUS 8.0 (TIBCO Software Inc, CA, USA). 
We calculated EC50 of remifentanil blunting the hemodynamic 
response to tracheal intubation with derived data by Dixon’s 
up-and-down method [4]. Statistical significance was declared 
if P < 0.05.
Results
    Twenty-six patients were enrolled in the study. There were 
24 patients with Mallampati class I and 2 with class II. Tracheal 
intubations were successful for the first trial in all patients. 
The average intubation time was 13.9 ± 9.1 seconds. In this 
study, ephedrine or atropine was not administered in any case. 
Individual responses to tracheal intubation according to the 
up-and-down sequence in patients receiving target-controlled 
effect-site concentration of remifentanil are shown in Fig. 1. 
The changes of hemodynamic responses (e.g. mean arterial 
pressure and heart rate) to endotracheal intubation are shown 
in Table 2.
    After induction of anesthesia with 4 μg/ml of propofol 
concentration, we calculated the EC50 of remifentanil for 
blunting hemodynamic response to tracheal intubation with 
Surch-Lite
Ⓡ by Dixon’s equation from his original papers 
[4]. In our study, N is more than 6, thus EC50 estimate can be 
calculated by a factor which is dependent on the constant A and 
C on tables from original Dixon’s paper [4]. The estimate is as 
below:
    Where N is total number of patients, d is difference between 
dose levels (0.5 ng/ml), Xi are the test levels (from 2.0 ng/ml to 
5.0 ng/ml) and A and C are obtained from the original paper 
[4]. Therefore, the mean EC50 of remifentanil blunting the 
hemodynamic response to tracheal intubation with Surch-Lite
Ⓡ 
was 2.94 ng/ml.
Discussion
    This study shows EC50 of the effect-site concentration of 
remifentanil to blunt hemodynamic change induced by tracheal 
intubation with Surch-Lite
Ⓡ was 2.94 ng/ml after induction of 
anesthesia using propofol of 4 μg/ml. Tracheal intubation is 
associated with transient increases in systemic blood pressure 
and heart rate due to sympathetic stimulation. According to 
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Table 2. The Change of Hemodynamic Variables During the Study 
Recording time points MAP (mmHg) HR (beats/min)
Before induction of anesthesia
Before starting remifentanil infusion
On achieving the remifentanil targeted concentration
Immediately after tracheal intubation
1 minute after tracheal intubation
2 minute after tracheal intubation
3 minute after tracheal intubation
4 minute after tracheal intubation
89.7 ± 9.9
86.5 ± 11.7
77.8 ± 8.8
74.5 ± 9.3
87.4 ± 14.3
80.4 ± 11.6
73.0 ± 9.7
74.1 ± 12.5
79.0 ± 17.0
80.7 ± 15.5
70.8 ± 12.2
72.9 ± 14.5
90.1 ± 15.8
85.0 ± 17.1
79.7 ± 11.4
80.8 ± 13.3
Data are expressed as mean ± SD. MAP: mean arterial pressure, HR: heart rate.
Fig. 1. Individual responses to tracheal intubation according to the up-
and-down sequence in patients receiving target-controlled effect-
site concentration of remifentanil. The effect-site concentration 
of propofol was maintained at 4 μg/ml for all patients. If a patient 
showed any increase of either heart rate or mean arterial blood pre-
ssure (MAP) > 20% immediately before the start of the remifentanil 
infusion, the effect-site concentration of remifentanil given to the 
next patient was increased to 0.5 ng/ml of remifentanil (fail response; 
black cross mark). In the absence of either heart rate or MAP 
increasing > 20% immediately before the start of the remifentanil 
infusion, the effect-site concentration given to the next patient was 
decreased to 0.5 ng/ml (success response; black filled circle).401 www.ekja.org
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Hassan et al. [1], stimulation of proprioceptors at the base of 
the tongue during laryngoscope induces impulse-dependent 
increases in systemic blood pressure, heart rate and plasma 
catecholamine concentrations. The intensity of the stimulus 
exerted during laryngoscope is expressed by the product of its 
average force and duration. 
    Transillumination is an alternative method to direct laryngo-
scopic intubation for difficult intubations. However, the trans-
illumi  nation method also causes hemodynamic changes 
due to stimuli sympathetic tone when performing tracheal 
intubation [3]. We measured EC50 of effect-site concentration 
of remifentanil to blunt the hemodynamic change of tracheal 
intubation with Surch-Lite
Ⓡ during anesthesia with propofol 
and remifentanil.
    Many studies have been conducted on the concentration of 
pro  pofol required for appropriate unconsciousness when intra-
venous anesthesia was performed. Vuyk et al. [5] reported EC50 
and EC95 effect-site concentration to induce uncon  sciousness 
in 50% and 95% of patients, were 3.4 μg/ml and 4.34 μg/ml, 
respectively. Another study reported effect-site concentration 
of propofol for maintaining 41.1 ± 2.5 of bispectral index (BIS) 
was 3.5 μg/ml [6]. Based on these studies, we determined that 
the effect-site concentration of propofol was 4 μg/ml for gaining 
unconsciousness. 
    There have been many studies on the appropriate concen-
tration of remifentanil to blunt hemodynamic change 
during tracheal intubation. Shin et al. [7] reported effect site 
concentrations of remifentanil to blunt sympathetic responses 
to tracheal intubation. In 50% and 95% of patients receiving a 
BIS-guided propofol anesthesia, the results were 1.37 ng/ml for 
men and 1.05 ng/ml for women. Lee et al. [8] reported effect site 
concentration of remifentanil to blunt hemodynamic change 
induced by tracheal intubation was 4 ng/ml and 6 ng/ml among 
groups of 0, 2, 4 and 6 ng/ml. In using laryngeal mask airway 
(LMA), EC50 of remifentanil needed inserting LMA was 3.18 ng/
ml in patients receiving effect site concentration of propofol 
of 4 μg/ml [9]. In our study, we set 5 ng/ml of remifentanil as 
the initial effect site concentration based on results of previous 
studies on blunting the hemodynamic response during tracheal 
intubation [10].
    Lee et al. [11] reported effect-site concentration of remifen-
tanil with Surch-Lite
Ⓡ in their study which was performed on 
3 groups of 2, 4 and 6 ng/ml, and the appropriate effect-site 
concentration was 4 ng/ml. However, the drawback of their 
study was that the enrolled patients were divided into only 3 
groups and the gap between each group was wide. It seems 
that sensitivity of their results was lower than our results. 
Another drawback was that they stopped infusing remifentanil 
before tracheal intubation. We think stopping infusion affect 
their results in the case of long intubation time. Differently to 
other studies [12,13], we measured intubation time as a level 
of intubation stimuli, because intubation time can influence 
hemodynamic change induced by tracheal intubation [14]. 
Intubation time in our study was 13.9 ± 9.1 seconds and it 
was not significantly different from other studies. In studies of 
Hwang et al. [12] and Lee et al. [13], intubation times were 11.8 ± 
6.6 seconds and 13 ± 2 seconds respectively and our intubation 
time was shorter than intubation time of Kohki et al. [15] of 30 
seconds. Though we used appropriate propofol concentration 
based on other studies [5,6], we assessed loss of consciousness 
with eyelid reflex, not by using BIS. Objectivity about anesthetic 
depth was lower than other studies and it might affect our results. 
We used a noninvasive method for arterial blood pressure 
measurement such as that of Albertin et al. Though it did not 
show continuous results, we secured relatively correct result 
through short interval of measuring arterial blood pressure. If 
we had used systemic vascular resistance (SVR) and cardiac 
output or concentration of catecholamine as indicators of 
cardiovascular response, we could gain better results. Moreover, 
in this study we have selected only patients with normal airway 
anatomy. In the previous report of Wong et al., they showed 
that obesity (BMI ≥ 30 kg/m
2) and Mallampati class III/IV 
were major factors of difficulty of intubation using light wand 
[16]. Therefore, in clinical settings, it is possible that higher 
concentration of remifentanil would be required compared to 
our results, especially in patients with difficult airways.
    In conclusion, the effect-site concentrations of remifentanil 
of 2.94 ng/ml is effective in blunting sympathetic responses 
to tracheal intubation with Surch-Lite
Ⓡ in 50% of patients 
with a normal airway anatomy when combined with a target 
controlled infusion of propofol (4 μg/ml).
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